title: [Antibody therapy for Alzheimer's disease].
abstract: In order to avoid Abeta-induced autoimmune encephalitis, several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different. It is unknown which antibody is effective for Alzheimer disease, and we must wait for the result of clinical trials. Some patients who developed tissue amyloid plaque immuno-reactive (TAPIR) antibody showed slower decline after AN-1792 vaccination. We developed TAPIR-like monoclonal antibody, which was found to react with Abeta oligomers preferentially.
authors.affiliation: Department of Diagnosis, Prevention and Treatment of Dementia, Graduate School of Medicine, Juntendo University.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tabira
authors.forename: Shin-Ei
authors.initials: SE
authors.lastname: Matsumoto
authors.forename: Haifeng
authors.initials: H
authors.lastname: Jin
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D051379:Mice
chemical_list: D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal